Biogen Inc. has received $4.95 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 17 Financial Advisor in the Stock Trading Firms. Among 17 Analysts, Bottom line EPS Estimate for the current quarter is $4.27 while the top line estimate is $5.58 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 3.29%.
Biogen Inc. reported better than expected with a surprise EPS of 1.41% or $0.07 during its most recent quarterly earnings. The Actual EPS was $5.04 compared to the Estimated EPS of $4.97. Cambridge based Biogen Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Apr 20, 2017.
Biogen Inc. has a Price to Earnings ratio of 13.65 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 4.91. For the Most Recent Fiscal Year, Biogen Inc. has a price to cash ratio of 12.4. For the Trailing twelve month period, company showed a Net Profit Margin of 32.34% and Return on Equity of the stock is 38.48%.
In the last quarter, Biogen Inc. reported Annual Earnings of $5.04. Based on the filings, last years Annual Earnings was, $20.22. In the last Quarter, BIIB reported a surprise Earnings per Share of 1.41% . The consensus estimate for current quarter is $4.95 and for the current fiscal year, the estimate is $21.06. For the Next fiscal year, the estimate is $22.5 based on the consensus.
Biogen Inc. (NASDAQ:BIIB) : On Tuesday heightened volatility was witnessed in Biogen Inc. (NASDAQ:BIIB) which led to swings in the share price. The stock opened for trading at $275.01 and hit $278 on the upside , eventually ending the session at $277.24, with a gain of 0.43% or 1.18 points. The heightened volatility saw the trading volume jump to 1,856,355 shares. The 52-week high of the share price is $333.65 and the company has a market cap of $59,884 million. The 52-week low of the share price is at $223.0211 .
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimers disease, lupus nephritis to neuropathic pain.